Aug 2, 2017
Dr. Dror Harats, Founder and CEO of VBL Therapeutics, talks about the limitations of current treatments for recurrent glioblastoma multiforme (rGBM), the most common and deadliest form of brain cancer in adults and the challenges in developing new treatments to combat this devastating disease. The good news is that their lead candidate, a biologic agent called VB-111, is in late-stage clinical development for rGBM and showing great promise. He discusses the unique mechanism of VB-111 that he hopes could hold the key not only to treating rGBM, but many types of cancer.
#BrainTumor #BrainCancer. #Cancer
VBL Therapeutics VBLRX.com